Cargando…

Targeted therapies for renal cell carcinoma in Chinese patients: focus on everolimus

Renal cell carcinoma (RCC) is the most common type of cancer arising from the kidney, with a male to female ratio of 2:1. The incidence of RCC is rising. In males, it was the seventh most common cancer in the People’s Republic of China in 2012. RCC is resistant to radiotherapy and chemotherapy, but...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tan, Xiaojie, Liu, Yan, Hou, Jianguo, Cao, Guangwen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4321650/ https://www.ncbi.nlm.nih.gov/pubmed/25674006 http://dx.doi.org/10.2147/OTT.S64660

Ejemplares similares

Establishment and characterization of clear cell renal cell carcinoma cell lines with different metastatic potential from Chinese patients
por: Tan, Xiaojie, et al.
Publicado: (2013)

Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies
por: Grünwald, V, et al.
Publicado: (2011)

The Role of Everolimus in Renal Cell Carcinoma
por: Meskawi, Malek, et al.
Publicado: (2015)

Follistatin-like protein 1 plays a tumor suppressor role in clear-cell renal cell carcinoma
por: Liu, Yan, et al.
Publicado: (2018)

Role of everolimus in the treatment of renal cell carcinoma
por: George, Saby, et al.
Publicado: (2009)

A GWAS-identified susceptibility locus on chromosome 11q13.3 and its putative molecular target for prediction of postoperative prognosis of human renal cell carcinoma
por: SU, TONG, et al.
Publicado: (2013)

A genetic polymorphism affects the risk and prognosis of renal cell carcinoma: association with follistatin-like protein 1 expression
por: Liu, Yan, et al.
Publicado: (2016)

Everolimus – a new approach in the treatment of renal cell carcinoma
por: Anandappa, G, et al.
Publicado: (2010)

Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma
por: Rossetti, Sabrina, et al.
Publicado: (2017)

Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy
por: Buti, Sebastiano, et al.
Publicado: (2016)

Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma
por: Bendtsen, Mathias Alrø Fichtner, et al.
Publicado: (2017)

Synergic Effect of Metformin and Everolimus on Mitochondrial Dynamics of Renal Cell Carcinoma
por: Hong, Seong-Hwi, et al.
Publicado: (2022)

Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib
por: Serova, Maria, et al.
Publicado: (2016)

Safety and clinical efficacy of everolimus in the treatment of advanced renal cell carcinoma (RCC)
por: Shahani, Rohan, et al.
Publicado: (2010)

Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
por: Molina, Ana M., et al.
Publicado: (2010)

Everolimus (RAD001) in the Treatment of Advanced Renal Cell Carcinoma: A Review
por: Agarwala, Sanjiv S., et al.
Publicado: (2010)

Clinical experience and critical evaluation of the role of everolimus in advanced renal cell carcinoma
por: Sun, Maxine, et al.
Publicado: (2011)

Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma
por: Leonetti, Alessandro, et al.
Publicado: (2017)

Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy
por: Choueiri, Toni K, et al.
Publicado: (2022)

The use of everolimus in renal-transplant patients
por: Pascual, Julio
Publicado: (2009)

Everolimus and/or Nivolumab-Associated Cytomegalovirus Colitis in a Patient with Metastatic Renal Cell Carcinoma
por: Ismayilov, Rashad, et al.
Publicado: (2022)

An Overview of Systemic Targeted Therapy in Renal Cell Carcinoma, with a Focus on Metastatic Renal Cell Carcinoma and Brain Metastases
por: Semenescu, Liliana Eleonora, et al.
Publicado: (2023)

Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma
por: Li, Siming, et al.
Publicado: (2014)

Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
por: Powles, Thomas, et al.
Publicado: (2018)

FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer
por: Chen, James L, et al.
Publicado: (2013)

Combination of Everolimus with Sorafenib for Solid Renal Tumors in Tsc2(+/−) Mice Is Superior to Everolimus Alone()
por: Yang, Jian, et al.
Publicado: (2017)

The use of everolimus to target carcinogenic pathways in a patient with renal cell carcinoma and tuberous sclerosis complex: a case report
por: Kim, Hye Sook, et al.
Publicado: (2014)

Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma
por: Lee, Chung-Han, et al.
Publicado: (2021)

Everolimus in Invasive Malignant Renal Epithelioid Angiomyolipoma
por: Guo, Gang, et al.
Publicado: (2021)

Everolimus in metastatic renal cell carcinoma after failure of initial anti–VEGF therapy: final results of a noninterventional study
por: Bergmann, Lothar, et al.
Publicado: (2015)

Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis
por: Bracarda, S, et al.
Publicado: (2012)

Immunological effects of everolimus in patients with metastatic renal cell cancer
por: Huijts, Charlotte M, et al.
Publicado: (2017)

Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma
por: Sheng, Xinan, et al.
Publicado: (2020)

Targeted treatments in advanced renal cell carcinoma: focus on axitinib
por: Verzoni, Elena, et al.
Publicado: (2014)

Mutational analysis of renal angiomyolipoma associated with tuberous sclerosis complex and the outcome of short-term everolimus therapy
por: Ni, Jianxin, et al.
Publicado: (2019)

Targeted therapy for renal cell carcinoma: The next lap
por: Kanesvaran, Ravindran, et al.
Publicado: (2014)

Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma
por: Santos, C D, et al.
Publicado: (2015)

Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma
por: Motzer, Robert J., et al.
Publicado: (2018)

Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma
por: Huijts, Charlotte M., et al.
Publicado: (2018)

Everolimus-induced activation of latent Mycobacterium tuberculosis infection in a patient with metastatic renal cell carcinoma
por: Jeon, So-Yeon, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_psdh4aeu8k3g5v4tevlh0717vu